1. Introduction {#s0005}
===============

Mayer-Rokitansky-Kuster-Hauser syndrome (MRKHS) is a müllerian duct anomaly characterized by segmental or complete agenesis/hypoplasia of the upper vagina, uterus and, less frequently, fallopian tubes. Its prevalence worldwide is about 1:4500 live female births, representing one of the most frequent congenital malformation affecting the female genital tract and a common cause of primary amenorrhea. Malformations observed in MRKHS may be confined to the müllerian duct (MRKHS type 1 syndrome, Online Mendelian Inheritance in Man reference -- OMIM %277000) or involve also other structures, including renal, skeletal, auditory and cardiac (MRKHS type 2 and MUllerian duct aplasia, Renal agenesis/ectopia, Cervical Somite dysplasia -MURCS, OMIM %601076).

The etiological basis of the syndrome is yet to be defined. Most cases are sporadic, though familial clustering has been reported, suggesting a putative genetic origin of the syndrome. However, data on genetic and genomic alterations identified in MRKHS patients, as well as the observed patterns of inheritance, are consistent with a polygenic/multifactorial disorder ([@bb0015]).

In only a few MRKHS cases the occurrence of gynecological cancer was reported. Of particular interest was the report of Huepenbecker et al. describing two sisters affected with MRKHS, who also developed serous ovarian carcinoma ([@bb0025]). This finding raised the possibility of a shared genetic origin of the two conditions, although data concerning the association of ovarian cancer with MRKHS are still limited.

Herein we report an additional case of serous ovarian carcinoma occurring in a 33-year old woman affected with MRKHS.

2. Case {#s0010}
=======

A 33-year-old Caucasian woman was referred to our Centre for the assessment of an abdominal mass.

Due to primary amenorrhea, at the age of 14 years she underwent gynecological investigations revealing a blind vagina, small rudimentary uterus (3.91 × 1.13 cm), two fully developed tubes and normal ovaries, which led to the diagnosis of MRKH syndrome. No additional malformations were detected at abdominal ultrasound (US) scan and spinal X-ray, with the exception of a slight s-shaped scoliosis. Karyotype analysis resulted normal (46,XX). Her past medical history was unremarkable for other medical conditions.

One month before being referred to our Centre, the patient had experienced abdominal pain and underwent a computed tomography scan revealing the presence of large bilateral ovarian masses with solid and cystic components. Transabdominal and transvaginal US were performed on admission, which showed bilateral adnexal masses with solid components, extending into the pelvis, and monolateral crescent sign. Right adnexal mass measured 65×58×74 mm, left mass measured 35×37×34 mm. A small uterus with no endometrial cavity was identified. A diagnosis of borderline ovarian tumor vs. carcinoma was suspected and a surgical approach was discussed with the patient.

Preoperative CA-125 level was elevated (3488 U/ml), other tumor markers (CEA, AFP, CA15.3, CA19.9) were in the normal range. Radical surgery with bilateral salpingo-oophorectomy, omentectomy and pelvic lymphadenectomy was performed. Surgical findings included multiple omental and peritoneal nodules, adnexal masses (max diameter: right 70 mm, left 40 mm) with papillary vegetations and uterine aplasia. Samples from peritoneal washing and multiple peritoneal biopsies were obtained. Hystopatological examination evidenced a low-grade serous carcinoma at both the ovaries, which was also localized at the anterior wall of the rectum; fallopian tubes showed no neoplastic invasion. Findings of the omental and peritoneal nodules included psammoma bodies and no evidence of cancer cells. No signs of residual disease were detected and the tumor was staged IIB (FIGO). Postoperative recovery was unremarkable. The patient received six cycles of adjuvant chemotherapy with carboplatin.

Due to the personal history of early onset ovarian carcinoma, the patient was referred to genetic counseling. At pedigree evaluation, the patient reported a post-menopausal breast cancer in her paternal grandmother, Hodgkin disease in the paternal grandfather and colon cancer in a maternal uncle. Although her cancer family history was not suggestive of a specific cancer predisposition syndrome, *BRCA1* and *BRCA2* analysis was discussed and performed by means of Next Generation sequencing and multiplex ligation-dependent probe amplification (MLPA), which resulted negative for either germline pathogenic variants or variants of uncertain significance.

3. Discussion {#s0015}
=============

Ovarian cancer (OC) is a common gynecological disease with \>230′000 new cases per year worldwide, accounting for about 3,5% of all newly diagnosed cancers. The estimated lifetime risk of developing OC is 1,3%, although incidence varies widely depending on both age and histological type.

\>90% of ovarian malignancies are of epithelial origin, which include five main histological subtypes: high-grade serous (HGSOC, \~70%), endometrioid (\~10%), clear cell (\~10%), mucinous (\~3%) and low-grade serous (LGSOC, \<5%). Non-epithelial histologies, which account for about 10% of OCs, include sex-cord stromal tumor (\~5%) and germ cell tumor (\~2%). For all epithelial subtypes, incidence rates before ages 35--39 are very low. However, the incidence steadily increases with age, reaching the highest rate at 70--80 years. Notably, at ages younger than 30 years the incidence of other histotypes is higher than that of epithelial OC ([@bb0010]).

According to these data, albeit OC is not a rare disease, our patient affected with LGSOC at the age of 33 years developed an infrequent tumor at an uncommon age. Due to the atypical presentation, a possible genetic predisposition was considered.

The main susceptibility genes associated with an increased risk of OC are *BRCA1* and *BRCA2*, although pathogenic variants in these genes usually underlie the development of HGSOC but not LGSOC. Despite the tumor histotype, due to the very early age at onset, genetic testing of the *BRCA1/2* genes was offered to the patient. The analysis resulted negative for germline variants, confirming the hypothesis of a different pathomechanism for LGSOC. Other genetic analyses were not considered because the patient\'s family history was not suggestive for any specific cancer predisposition syndrome (eg. Lynch syndrome).

In patients with MRKHS, OC is only occasionally described. To the best of our knowledge, only 14 cases have been reported worldwide: four from Europe, five from Asia and five from America. Information concerning patients affected with both MRKHS and OC are summarized in [Table 1](#t0005){ref-type="table"}. Among all MRKHS patients with OC, eight (53%) developed an epithelial cancer, most of the serous type (5/8), four (27%) developed a germ cell tumor and three (20%) a sex-cord stromal tumor. None of the previously reported patient developed a LGSOC. Median age at onset was 55 years (range 31--68) for epithelial tumors, 30 years (range 4--79) for non-epithelial tumors. Although the limited number of cases is not suitable for a statistical analysis, epithelial cancers appear to occur at a younger age in MRKHS patients compared with the general population. Of note, two additional patients from Korea were diagnosed before age 40 years. However, the OC described by Bae and colleagues ([@bb0005]), arose from a supernumerary pelvic ovary, which could be at higher risk for tumor development.Table 1Cases of Mayer-Rokitansky-Küster-Hauser syndrome (MRKHS) patients affected with ovarian tumors.Table 1ArticleCountryMRKHS typeOvarian tumor age at onsetOvarian tumor histologyOvarian tumor typeOvarian tumor gradeOvarian tumor stage (FIGO)([@bb0045])United StatesI26Germ cellYolk sac tumor[a](#tf0005){ref-type="table-fn"}naI([@bb0050])CanadaII34Sex-cord stromalSertoli cell[b](#tf0010){ref-type="table-fn"}III([@bb0065])GermanyII79Sex-cord stromalBilat. Sertoli cellIIna([@bb0075])ChinaI4Germ cellImmature teratomaIII([@bb0020])ItalyI68EpithelialUndifferentiated carcinomaIIIIII([@bb0070])Japanna8Germ cellYolk sac tumornaI([@bb0055])Moldovana35Germ cellDysgerminomanaI([@bb0035])GermanyII48EpithelialMixed epithelial carcinomaIIIIII([@bb0005])KoreaII31EpithelialSerous papillary[c](#tf0015){ref-type="table-fn"}naIII([@bb0040])KoreaII37EpithelialSerous carcinomaIIIIII([@bb0060])IndiaII65EpithelialEndometrioid carcinomanaI([@bb0030])United StatesI72Sex-cord stromalBilat. Sex-cord stromal tumornaI([@bb0025])United Statesna64EpithelialSerous carcinomaIIIIIIna63EpithelialSerous tubal carcinomaIIIIIIPresent CaseItalyI33EpithelialBilat. Serous carcinomaIII[^1][^2][^3][^4]

Genetic testing in other cases was not performed, with the exception of the two sisters reported by Huepenbecker, who were affected with MRKHS and developed HGSOC at the age of 63 and 64 years respectively. Both these patients resulted negative for pathogenic variants in *BRCA1/2* and other 31 cancer susceptibility genes ([@bb0025]). Moreover, no data on cancer family history are available for previously reported patients, therefore it is not possible to rule out that a putative cancer-predisposing syndrome might explain a subset of these cases.

4. Conclusions {#s0020}
==============

In conclusion, we report on a new case of co-occurrence of MRKHS and OC and provide an updated review of the literature. To date, there is no evidence of an involvement of known cancer genes in MRKHS, as opposed to other genitourinary malformation syndromes, such as Denys-Drash syndrome (OMIM \#194080) or WAGR (OMIM \#194072), both characterized by a loss of function of the WT1 gene. Since the available data and knowledge about the etiopathological factors underlying the syndrome are still limited, it is not possible to define a putative correlation between MRKHS and increased risk for OC. The collection of further data and reports of additional cases will thus be crucial in order to either confirm or rule out a possible common pathomechanism underpinning MRKHS and OC.

4.1. Consent {#s0025}
------------
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[^1]: na, not available.

[^2]: Previous diagnosis of femur osteosarcoma at the age of 25, no chemotherapy or radiation therapy.

[^3]: Borderline tumor of the other ovary.

[^4]: Supernumerary ovary.
